Technology
Health
Pharmaceutical

Flex Pharma

$0.382
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0027 (0.71%) Today
+$0.0009 (0.24%) After Hours

Why Robinhood?

You can buy or sell Flex Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. Read More The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.

Employees
4
Headquarters
Boston, Massachusetts
Founded
2014
Market Cap
6.84M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
965.05K
High Today
$0.41
Low Today
$0.37
Open Price
$0.379
Volume
275.94K
52 Week High
$7.22
52 Week Low
$0.26

Collections

Technology
Health
Pharmaceutical
Medical
Biotechnology
2015 IPO
US
North America

News

Markets InsiderFeb 26

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flex Pharma, Inc. - FLKS

NEW YORK, Feb. 26, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of Flex Pharma, Inc. ("FLKS" or the "Company") (NasdaqCM: FLKS) related to the sale of the company to Salarius Pharmaceuticals, LLC. Under the terms of the proposed transaction, FLKS stockholders will own 19.9% of the combined company upon completion of the transacti...

3,052

Earnings

-$0.58
-$0.42
-$0.27
-$0.11
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.